ClinicalTrials.gg
Status unknownNCT00717509Updated Jun 12, 2009

Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia

An observational study in Schizophrenia, Metabolic Syndrome and Genetic Polymorphism, sponsored by Seoul National Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-12.

Sponsored by Seoul National Hospital · Observational

How we know

The sponsor has not verified this record recently (last verified Jun 2009), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Schizophrenia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Korea, Republic of.

Planned enrollment
11th of 23
150 · median 100
Started
2007
with 10 others
Observational
23 of 112
none open now
Registered
26th of 112
by date

Among the 112 studies in Schizophrenia with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 23 observational ones that give a count, is one of 11 that started in 2007, is one of 23 observational ones, and was the 26th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 112 studies in Schizophrenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Schizophrenia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.

Read the detailed description

The use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes.

The prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. The high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant.

The genotypes of the multiple gene such as HTR2C, LEP, adrenergic receptor,PPAR,GNB3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome) in patients using antipsychotics.

We are going to investigate whether those multiple genetic polymorphisms are associated with the metabolic side effects in patients taking clozapine.

03

Conditions studied

  • Schizophrenia
  • Metabolic Syndrome
  • Genetic Polymorphism

Keywords

  • schizophrenia
  • metabolic side effect
  • clozapine
  • genetic polymorphism
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with schizophrenia taking clozapine more than 1 year

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-65
  • who can understand and sign the

Exclusion criteria

Exclusion Criteria:

  • who refuse to participate this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • clozapine group

    * chronic schizophrenia * have been taking clozapine at leaset one year * without diabetes, pulmonary tuberculosis

06

What researchers measure

Primary outcomes

  1. The associations between multiplegenetic polymorphisms (HTR2C,leptin,adrenergic receptor,PPAR,GNB3) and the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome)

    Time frame: more than 1 year after starting clozapine

07

Study locations

1 of 1 sites recruiting
  • Seoul National Hospital
    Seoul, 139-757, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jan 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Jul 17, 2008
Start
Oct 2007
Primary completionActual
Jan 2009
CompletionEst.
Oct 2009
Last update
Jun 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00717509
Lead sponsor
Seoul National Hospital
First posted
Jul 17, 2008
Start date
Oct 2007
Primary completion
Jan 2009
Completion
Oct 2009 (estimated)
Last update
Jun 12, 2009

Study contacts

Shi Hyun Kang, M.D.
Contact
drshe@hanmail.net
82-2-2204-0326
Shi Hyun Kang, M.D.
study director · Seoul National Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion